Miss income? Ampen’s dividend is still a bright spot News ad

Amgen Inc. (NASDAQ: AMGN) Promotions decreased by about 1.4% in non -working hours, despite the fact that in the income report in the fourth quarter of 2024 exceeded estimates. Investors, apparently, are selling news about the last cure for the obesity of AMG-513, which was involved in the clinical retention of FDA. The drug entered into the testing of phase 1 at the end of 2024.

As for the report itself, AMGEN announced a profit per share (EPS) in the amount of $ 5.31 with an income of $ 9.09 billion. Both numbers surpassed analysts for an action in the amount of $ 5.08 for revenue in the amount of $ 8.88 billion. USA.

The key number, by the same, is the upper lines of 10%, which is psychologically important for investors that expect the company to be blocked in a cycle that will limit the growth of income in high unambiguous numbers.

Nevertheless, AMGEN recommendations for income can also be behind the slide after dinner. The company expects the revenue from $ 34.4 billion. USA to 35.7 billion dollars. USA. The average point of this leadership corresponds to the assessments of analysts. Nevertheless, at the upper end of this range, the revenue growth compared to the same period last year will be 6%. As a result, the company expects EPS from 20 to 21.20 US dollars, which also corresponds to analysts.

Investors were very interested in hearing updated information about AMGEN, AMG-513 and Maritide drug candidates. As noted above, the FDA put the AMG-513 in clinical retention. The Akgen says that this is in discussions with FDA to open a study, but investors clearly sell first and look at the details later.

However, this is not the only entrance to the company to the obesity market and weight loss. At the end of November 2024, AMGEN reported Positive data from the clinical testing of phase 2 For Maritida in patients who used the product for 52 weeks. The results showed that patients experienced approximately 20% of average weight loss without getting into the plateau.

Maritide is an invoice for obesity, which also contains glucose -dependent insulinotropic polypeptide receptor antagonists (GIPR). They are designed to block GIP hormones that affect blood sugar, fat storage and appetite.

Secondly, Maritid should introduce only once a month or even less. This eliminates one of the key objections to patients with current GLP-1 preparations, which must be taken weekly.

And three, the results of the study of the early phase 2 showed that patients reported less side effects, especially digestive ones. As a rule, this is the reason why patients stop their medicines for losing weight. Nevertheless, AMGEN reported that only 11% of the test participants decided to stop taking the drug, and less than 8% did this from the side effects of digestion.

Currently, the company conducts the second half of this study of the phase 2, and the drug will have to undergo a phase 3 study before it can be commercially approved. The company confirmed that it was on the way to the beginning in the middle of the year. Nevertheless, investors still have to wait before the influence of Maritida enters the upper and results of Amgen.

Anggen is one of the Dow Dogs. This is a list consisting of 10 Dow Jones shares with the highest dividend yield. These shares historically exceeded the wider Dow Jones Industrial Average (DJIA), which makes them attractive to investors.

Anggen concluded this list in 2024 and has a profitability of 3.12%, heading for profit. Dividends also annual growth of dividends by 3 years amounted to more than 8.5%, which is more than 50% higher than on average for medical actions. So far, the strategy can work. AMGN shares increased by about 10.6% in 2025. However, over the past 12 months, it has still decreased by about 10.8%. This still leaves a lot of growth for investors who are looking for growth and income.

And although analysts reduce their target prices on the eve of the income report, the consensus target price of $ 314 will provide investors with an increase of 8% to achieve attractive dividends.

In the short term, they will have to deal with a bear card. About $ 289, the relative force indicator (RSI) indicates that the action has been replaced. This can send a share about $ 273, which would bring its 50-day simple sliding average. At this level, growth will be more difficult to miss.